Recent Updates
Recently added Catalysts

Bisacodyl

Phase 2

Postoperative Nausea and Vomiting | Small molecule | Pain |The Cooper Companies, Inc.|Last Updated: Jan 19, 2014

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment285
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01011426Bisacodyl Use in the Post-operative Care of Obstetrical/Gynecological (OB/GYN) PatientsPHASE2 COMPLETED 285Apr 1, 2009Jun 1, 2012Jan 19, 2014 -
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
BisacodylDRUG5mg po 6 hours postoperatively, repeat in 12 hours if no flatus
placeboDRUG1 capsule po 6 hours after surgery; repeat in 12 hours if no flatus
Unlock Study Design Details